Targeted therapy for malignant melanoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Advanced melanoma treatment has evolved significantly, moving from frustrating outcomes to improved patient survival.
• Targeted therapies, including BRAF inhibitors and immune checkpoint inhibitors, represent major advancements.
• Approximately 50% of melanomas harbor a BRAF mutation, driving cancerous growth via the MAP kinase pathway.

Purpose of the Study:

• To review the advancements in targeted therapy for advanced melanoma, focusing on BRAF and MEK inhibitors.
• To discuss the mechanisms of action and limitations of BRAF inhibitors, including resistance and adverse events.
• To highlight the improved outcomes with combination BRAF and MEK inhibitor therapy.

Main Methods:

• Review of current literature on targeted therapy for advanced melanoma.
• Analysis of the mitogen-activated protein kinase (MAPK) pathway in BRAF-mutated melanoma.
• Comparison of progression-free survival data for chemotherapy, BRAF inhibitors, and BRAF/MEK inhibitor combinations.

Main Results:

• BRAF inhibitors block the hyperactive BRAF kinase in mutated melanoma cells, but resistance can develop.
• Combination therapy with BRAF and MEK inhibitors counteracts resistance mechanisms and improves efficacy.
• Progression-free survival increased from 2 months (chemotherapy) to 7-8 months (BRAF inhibitor) to 10-14 months (BRAF/MEK inhibitor combination).

Conclusions:

• Targeted therapy, particularly BRAF and MEK inhibitor combinations, has revolutionized advanced melanoma treatment.
• Understanding resistance mechanisms is crucial for optimizing long-term patient outcomes.
• Combination therapy represents a significant improvement in progression-free survival for patients with BRAF-mutated melanoma.